{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=38",
    "query": {
      "condition": "Recombinant",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 1029,
    "total_pages": 103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T04:25:03.929Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02432144",
      "title": "A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sly Syndrome",
        "MPS VII",
        "Mucopolysaccharidosis",
        "Mucopolysaccharidosis VII"
      ],
      "interventions": [
        {
          "name": "UX003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-11-10",
      "completion_date": "2019-01-14",
      "has_results": true,
      "last_update_posted_date": "2020-07-30",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 4,
      "location_summary": "Oakland, California • Orange, California • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432144"
    },
    {
      "nct_id": "NCT03699241",
      "title": "A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 SOSIP.664 gp140, adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-12-03",
      "completion_date": "2023-07-11",
      "has_results": false,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699241"
    },
    {
      "nct_id": "NCT00606086",
      "title": "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Genotype 1 Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "GI-5005",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon and Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlobeImmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2007-12",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606086"
    },
    {
      "nct_id": "NCT01352143",
      "title": "Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiopulmonary Bypass"
      ],
      "interventions": [
        {
          "name": "Recombinant activated factor VII",
          "type": "DRUG"
        },
        {
          "name": "Prothrombin Complex Concentrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "Up to 30 Days"
      },
      "enrollment_count": 24,
      "start_date": "2011-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-11-20",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352143"
    },
    {
      "nct_id": "NCT02715804",
      "title": "A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Ductal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2016-03-14",
      "completion_date": "2019-11-04",
      "has_results": true,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 64,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715804"
    },
    {
      "nct_id": "NCT02450838",
      "title": "Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "V180",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02450838"
    },
    {
      "nct_id": "NCT01100528",
      "title": "Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ciliary Body and Choroid Melanoma, Medium/Large Size",
        "Ciliary Body and Choroid Melanoma, Small Size",
        "Iris Melanoma",
        "Recurrent Intraocular Melanoma"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 38,
      "start_date": "2009-11-11",
      "completion_date": "2017-12-14",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100528"
    },
    {
      "nct_id": "NCT05468736",
      "title": "Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 3600,
      "start_date": "2022-07-22",
      "completion_date": "2025-10-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 47,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05468736"
    },
    {
      "nct_id": "NCT00752557",
      "title": "Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)",
          "type": "DRUG"
        },
        {
          "name": "bisphosphonates, calcium, and vitamin D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "65 Years to 85 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2008-12-03",
      "completion_date": "2015-04-24",
      "has_results": true,
      "last_update_posted_date": "2020-03-20",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752557"
    },
    {
      "nct_id": "NCT00798265",
      "title": "A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Human Papillomavirus- 6, 11, 16, 18",
        "Adolescent",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Gardasil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "BEHAVIORAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "12 Years to 26 Years"
      },
      "enrollment_count": 26,
      "start_date": "2009-06-29",
      "completion_date": "2013-02-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-28T04:25:03.929Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798265"
    }
  ]
}